Novavax, Inc.
NVAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $70 | $239 | $667 | $88 |
| % Growth | -70.6% | -64.1% | 654.9% | – |
| Cost of Goods Sold | $21 | $14 | $14 | $37 |
| Gross Profit | $49 | $225 | $653 | $52 |
| % Margin | 69.5% | 94.1% | 97.9% | 58.5% |
| R&D Expenses | $98 | $78 | $89 | $104 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $32 | $41 | $48 | $78 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $97 | $1 | $0 | $0 |
| Operating Expenses | $227 | $119 | $137 | $183 |
| Operating Income | -$178 | $106 | $516 | -$131 |
| % Margin | -252.7% | 44.2% | 77.3% | -148.4% |
| Other Income/Exp. Net | -$25 | $2 | $4 | $57 |
| Pre-Tax Income | -$203 | $107 | $520 | -$74 |
| Tax Expense | -$1 | $1 | $1 | $7 |
| Net Income | -$202 | $107 | $519 | -$81 |
| % Margin | -287.3% | 44.5% | 77.8% | -91.8% |
| EPS | -1.25 | 0.66 | 3.22 | -0.51 |
| % Growth | -289.4% | -79.5% | 731.4% | – |
| EPS Diluted | -1.25 | 0.6 | 2.93 | -0.51 |
| Weighted Avg Shares Out | 162 | 162 | 161 | 160 |
| Weighted Avg Shares Out Dil | 162 | 177 | 178 | 160 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $6 | $6 | $8 |
| Depreciation & Amortization | $7 | $8 | $8 | $13 |
| EBITDA | -$191 | $121 | $534 | -$53 |
| % Margin | -271.1% | 50.4% | 80.1% | -60.6% |